Prezalumab

Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) [1][2].

Product Specifications

CAS Number

[1523164-68-2]

Product Name Alternative

AMG 557

UNSPSC

12352203

Target

Interleukin Related; Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/prezalumab.html

Purity

99.23

Solubility

10 mM in DMSO

Smiles

[Prezalumab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Dillon SR, et al. Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) . Arthritis Rheumatol. 2023 Aug;75 (8) :1344-1356.|[2]Cheng LE, et al. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018 Jul;70 (7) :1071-1076.